This article was originally published in a journal published by OMICS Publishing Group, and the attached copy is provided by OMICS Publishing Group for the author's benefit and for the benefit of the author's institution, for commercial/research/educational use including without limitation use in instruction at your institution, sending it to specific colleagues that you know, and providing a copy to your institution’s administrator.

All other uses, reproduction and distribution, including without limitation commercial reprints, selling or licensing copies or access, or posting on open internet sites, your personal or institution’s website or repository, are requested to cite properly.

Digital Object Identifier: http://dx.doi.org/10.4172/2157-7536.1000119
Obesity, Circulating Androgens and their Precursors

Michaela Dušková, Hana Pospíšilová, Martin Hill and Luboslav Stárka*

Institute of Endocrinology, Prague, Czech Republic

Abstract

Objective: The association of obesity with a lower circulating testosterone level in men is well documented. However, reports on possible changes in the androgen spectrum in obesity are rare.

Methods: To investigate this phenomenon, serum sex hormone–binding globulin (SHBG), testosterone, dihydrotestosterone, androstenedione, dehydroepiandrosterone and its sulphate, 17α-hydroxypregnenolone, 17α-hydroxyprogesterone and gonadotrophins LH and FSH concentrations were measured in fasting blood samples of 224 men divided into three groups – normal (BMI=18-25, n=109), overweight (BMI 25.10-30, n=78) and obese (BMI=30.1-39, n=37).

Results: A significant decrease in testosterone, dihydrotestosterone, 17α-hydroxypregnenolone, 17α-hydroxyprogesterone and SHBG with increasing body mass index was observed, whereas insignificant changes for dehydroepiandrosterone and its sulphate, androstenedione and gonadotrophins LH and FSH, were found. The ratios of corresponding pairs of steroids were in agreement with the concept that in obesity splitting of the side chain of C19-steroids, and 17β-hydroxysteroid dehydrogenase-reducing activity are decreased. No changes for steroid 5α-reductase or 3β-hydroxysteroid dehydrogenase (HSD3B2) were found.

Conclusion: The findings demonstrate that, in men with increasing body mass index, the formation of C19-steroids decreases from their C19 precursors and lower 17β-hydroxysteroid dehydrogenase further confines the production of testosterone and dihydrotestosterone.

Keywords: Obesity; Testosterone; Dihydrotestosterone; Androgens; 17α-hydroxyprogesterone; 17α-hydroxypregnenolone

Introduction

Reduced testosterone levels, well into the hypogonadal range, are common in male obesity [1-5]. The mechanism of circulating total testosterone concentration decrease is explained by a high expression of aromatase, the enzyme that converts testosterone to estradiol, in adipose tissue and by the resulting elevated estradiol. Together with the increased leptin and adipokines from fat tissue, this triggers inhibition of the hypothalamic-pituitary-gonadal axis [6, 7]. This results in hypogonadotrophic hypogonadism, which is observed in a large percentage of obese men.

Whereas a handful of publications deal with the relation of testosterone, dihydrotestosterone or estradiol levels to obesity, less attention has been paid to the influence of obesity on androgen metabolism. Some important data were acquired by measuring the intra-adipose metabolism of androgens [8-10]. The activity of enzymes involved in androgen metabolism varies in the different parts of fat tissue and, together with local glucocorticoid activity, constitutes an important factor for fat distribution.

Data concerning circulating androgens and their precursors in obese men, with the exception of that on testosterone or dihydrotestosterone [11], are scarce [12-15]. This short study aims to determine the impact of obesity on the pattern of circulating androgens and to show whether all changes in the concentration of androgens and their precursors 17α-hydroxypregnenolone and 17α-hydroxyprogesterone are proportional to the reduced level of testosterone and if this decline also applies to androgens of mainly adrenal origin.

Materials and Methods

Subjects

A group of 224 healthy (except for their obesity and associated symptoms) men aged 20 to 78 with a broad range of body mass index (BMI) 18 to 39 was enrolled in this study. Anthropometric parameters (i.e. weight, height, BMI) were measured. Blood withdrawal was carried out in fasting subjects in the morning between 7:30 and 8:30 a.m. from the forearm vein. Serum was stored at -80°C until it was processed in the laboratory.

The Ethical Committee approved the study and all patients signed informed consent forms before taking part in the study.

Anthropometric data

Anthropometric data were obtained in a fasting state. Body weight and height were measured in all participants in order to calculate body mass index (BMI). Weight (to the nearest 0.1 kg) and height (to the nearest cm) were measured. Body mass index was calculated as the weight (kg) divided by height squared (m²).

The group of 224 healthy men was divided into three subgroups according to BMI. The first subgroup consisted of 109 men with BMI between 18 and 25. The second group included 78 men with BMI between 25 and 30. The third subgroup had 37 men with BMI 30 to 39.

Steroid analysis

Laboratory analyses of sex hormone binding globulin (SHBG),
LH, FSH and steroid hormones: dihydrotestosterone, testosterone, 17α-hydroxyprogesterone, dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), 4-androstene-3,17-dione (androstenedione), and 17α-hydroxyprogrenolone were carried out.

Serum testosterone was determined by standard radioimmunooassay (RIA) using antiserum anti-testosterone-3-carboxymethyloxim: BSA and testosterone-3-carboxymethyloxim-tyrosylmethyl-ester-[¹²⁵I] as a tracer. Intra-assay and inter-assay coefficient variants were 7.2% and 10%, respectively, and sensitivity was 0.21 nmol/l. Androstenedione was determined by standard RIA with antiserum anti-androstenedione-6-carboxy-methylloxim: BSA and [¹²⁵I] androstenedione as tracer. Intra-assay and inter-assay coefficient variants were 8.1% and 10.2% and sensitivity was 0.39 nmol/l. Sexual hormones binding globulin was assayed using an IRMA kit (Orion, Espoo, Finland). Commercial kits (Immunotech, Marseilles, France) were used for the determination of LH, FSH (IRMA kit), 17α-hydroxyprogesterone, dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS).

![Figure 1: Relationships between steroid levels, DHEAS/DHEA ratio and BMI as evaluated using ANCOVA with BMI group as a main factor and age of the subject as a covariate (for details see statistical data analysis). The circles with error bars represent the group means with their 95% confidence intervals as computed for least significant difference (LSD) multiple comparisons (p=0.05). The confidence values, which do not overlap, represent statistical significant difference between the corresponding groups. Statistical significance: NS=not significant, *p<0.05, **p<0.01, ***p<0.001.](image)
sulfate (DHEAS) (RIA kit). Dihydrotestosterone was determined by an original methodology [16,17]. 17α-Hydroxypregnenolone was determined by an in-house RIA method.

Statistical data analysis

To evaluate the relationships between dependent variables, we used the ANCOVA model with BMI group as a main factor and age of the subject as a covariate (age–adjusted ANOVA) followed by least significant difference (LSD) multiple comparisons. The original dependent variables and the covariate were transformed by power transformations to attain a constant variance and symmetric distribution of the data and residuals [18]. Statistical software Statgraphic Centurion version XVI (Herdon, VA, USA) was used for the calculations. The homogeneity of the data and residual were checked as described elsewhere [19].

Results

The comparison of men with normal body mass index, overweight and obese men showed that a significant continuous decrease of parameters for testosterone (Figure 2A), dihydrotestosterone (Figure 3A) and SHBG (Figure 2B) correlates with increasing body mass. Also the circulating both C₁₇α-androgen precursors, 17α-hydroxyprogesterone and 17α-hydroxyprogrenenolone, decrease with increasing BMI (Figures 1A and 1D), whereas the changes in androstenedione, DHEA, and DHEAS levels as well as in gonadotrophins do not reach statistical significance (Figures 1B, 1C and 1E). Since the decrease of SHBG (Figure 2B) parallels the decrease of testosterone level (Figure 2A), thus compensating the loss of free testosterone, no change was observed in the free androgen index (Figure 2C).

The dihydrotestosterone : testosterone ratio does not correlate with the degree of obesity (Figure 3B), to the 17α-hydroxyprogesterone : 17α-hydroxyprogrenenolone ratio or
androstenedione : dehydroepiandrosterone ratio (Figures 4A and 4B), which demonstrates the undisturbed activity of 3β-hydroxysteroid dehydrogenase type 2 (HSD3B2). On the contrary, it is evident from the DHEA : 17α-hydroxyprogrenenolone and androstenedione : 17α-hydroxprogesterone ratios (Figure 5A) that the activity of C19,20-lyase (CYP17A1) decreases with the degree of obesity, especially for the Δ4 pathway (Figure 5B).

The testosterone : androstenedione ratio (Figure 6) decreases significantly, which is in agreement with the decreased activity of 17β-hydroxysteroid dehydrogenase type 3 (HSD17B3).

Multivariate statistical analysis showed that age was a significant factor for the correlation of BMI and the levels of 17α-hydroxyprogrenenolone, 17α-hydroxyprogesterone, androstenedione, dehydroepiandrosterone and its sulfate and SHBG. The decrease of testosterone and dihydrotosterone with increasing BMI was independent of age.

No changes with increasing BMI were observed with regards to steroid 5α-reductase (SRD5A1) or 3β-hydroxysteroid dehydrogenase (HSD3B2).

These findings concur with the studies on in vitro metabolism of testosterone in the fat tissue of various localisations. In a study of intra-adipose sex steroid metabolism [9], generalized obesity (BMI) was associated with increased aromatase mRNA and 5α-reductase type 1 levels did not did not predict fat amount or its distribution. This supported the hypothesis that intra-adipose sex steroid metabolism is a determinant of gynoid vs. android patterns of body fat [9].

Modified androgen metabolism pathway influences fat tissue, as androgens modulate adipocyte function and affect the size of adipose tissue compartments in humans. For instance, aldo-keto reductase 1C (AKR1C) enzymes, especially AKR1C2 and AKR1C3, through local synthesis and inactivation of androgens, may be involved in the fine regulation of androgen availability in adipose tissue [10]. Type 3 17β-hydroxysteroid dehydrogenase is co-expressed with aromatase in abdominal preadipocytes [8].

It could be concluded that in men with increasing body mass index the formation of C19 steroids decreases from their C21 precursors, and lower 17β-hydroxysteroid dehydrogenase further confines the local synthesis and inactivation of androgens, which demonstrates the undisturbed activity of 3β-hydroxysteroid dehydrogenase type 2 (HSD3B2).

**Figure 6:** Relationships between steroid ratios reflecting the activity of type 3 17-hydroxysteroid dehydrogenase (HSD17B3) and BMI as evaluated using ANCOVA with BMI group as a main factor and age of the subject as a covariate (for details see statistical data analysis). The circles with error bars represent the group means with their 95% confidence intervals as computed for least significant difference (LSD) multiple comparisons (p=0.05). The confidence, which do not overlap represent statistical significant difference between the corresponding groups. Statistical significance: NS=not significant, *p<0.05, **p<0.01, ***p<0.001.
References